|
|
DDA Adjuvant |
|
Vaxjo ID |
15 |
|
Vaccine Adjuvant Name |
DDA Adjuvant |
|
Alternative Names |
Dimethyldioctadecylammonium bromide, Dimethy1dioctadecylammonium bromide; dimethy1distearylammonium bromide (CAS Registry Number 3700-67-2). |
|
Adjuvant VO ID |
VO_0001261
|
|
Description |
Dimethyldioctadecylammonium bromide (DDA) is a lipophilic quaternary ammonium salt known as a good adjuvant when co-administered systemically or nasally with an antigen. Furthermore this adjuvant is able to stimulate predominantly Th1 cells (Klinguer-Hamour et al., 2002). |
|
Stage of Development |
Clinical Trial |
|
Components |
Dimethyldioctadecylammonium bromide is a tetra-alkylammonium compound with long chain alkyl groups, which give it lipophilic properties. The alkyl groups of DDAB allow for its application in the preparation of cationic liposomes. Such liposomes may be used as DNA carrier systems for gene transfection and as vehicles for drug delivery (Sigma Aldrich). |
|
Molecular Weight |
631 |
|
Appearance |
White, odorless powder. |
|
Storage |
4-20° C. Protect from light. |
|
Preparation |
DDA micelles/antigen preparation - DDA preparations (ranging from 2 to 0.2 mg) were suspended in 900 μl of sterile-pyrogen free PBS, stirred for 2 min and warmed for 30 min at 62 °C. The solution were completed to 1 ml with sterile-pyrogen free PBS and stirred for 4 h at room temperature (Klinguer-Hamour et al., 2002). |
|
Dosage |
Dosage for Female specific pathogen free BALB/c mice and cotton rats: DDA suspension/antigen preparation - DDA powder (ranging from 20 to 1 mg) was suspended into 900 μl of sterile-progen free phosphate buffer saline (PBS) (Gibco Life Technologies, Cergy Pontoise, France). The solutions were completed to 1 ml with sterile-pyrogen free PBS and stirred for 4 h at room temperature (Klinguer-Hamour et al., 2002). |
|
Function |
A novel adjuvant consisting of the cationic surfactant dimethyldioctadecylammonium bromide (DDA) and α,α′-trehalose 6,6′-dibehenate (TDB) promotes a strong cell mediated immune response and a humoral immune response, which is essential for the induction of protective immunity against most diseases (Christensen et al., 2007). |
|
Safety |
DDA has already been injected to many people including pregnant women and children with no toxic effects reported (Klinguer-Hamour et al., 2002). |
| Related Vaccine(s) |
|
| References |
Christensen et al., 2007: Christensen D, Foged C, Rosenkrands I, Nielsen HM, Andersen P, Agger EM. Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying. Biochimica et biophysica acta. 2007; 1768(9); 2120-2129. [PubMed: 17555704].
Klinguer-Hamour et al., 2002: Klinguer-Hamour C, Libon C, Plotnicky-Gilquin H, Bussat MC, Revy L, Nguyen T, Bonnefoy JY, Corvaïa N, Beck A. DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine. Vaccine. 2002; 20(21-22); 2743-2751. [PubMed: 12034101].
Sigma Aldrich: Sigma Aldrich [http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Product_Information_Sheet/d2779pis.Par.0001.File.tmp/d2779pis.pdf]
|
|
